Abstract 11833: Cost-Effectiveness Analysis of the Polypill Approach vs Periodic Risk Assessment for Prevention of Cardiovascular Disease

Introduction: There is an international trend towards recommending medication to prevent cardiovascular disease (CVD) in individuals at increasingly lower cardiovascular risk. We sought to assess the cost-effectiveness of a population approach with a Polypill including statin and antihypertensives and periodic risk assessment with different risk thresholds. Methods: We developed a microsimulation model for lifetime predictions of CVD events, diabetes, and death in 259,146 asymptomatic UK Biobank participants aged 40 to 69, who attended 2006-2010 baseline visits. We assessed incremental costs and quality-adjusted life-years (QALYs) for Polypill scenarios differing for starting age, and periodic risk assessment with 10-year CVD risk thresholds of 10% and 20%. Analyses were undertaken from a UK health service perspective. Results: Restrictive risk assessment, in which statins and antihypertensives were prescribed when risk exceeded 20% (Old guidelines), was the optimal strategy gaining 123 QALYs (95% CI -173...